Loading
A phase 2 trial of Cemiplimab, Fianlimab in melanoma, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma is a phase 2 interventional study registered as NCT06190951 by Regeneron Pharmaceuticals, with 151 participants enrolled, started 2024-09-18 and due to reach its primary completion in 2026-11-02. Interventions recorded: cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Melanoma, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Melanoma.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/